CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases

Jing Zhang, Izabela Sokal, Elaine R. Peskind, Joseph F. Quinn, Joseph Jankovic, Christopher Kenney, Kathryn A. Chung, Steven P. Millard, John G. Nutt, Thomas J. Montine

Research output: Contribution to journalArticlepeer-review

248 Scopus citations


The therapeutic imperative for Alzheimer disease (AD) and Parkinson disease (PD) calls for discovery and validation of biomarkers. Increased cerebrospinal fluid (CSF) τ and decreased amyloid (A) β42 have been validated as biomarkers of AD. In contrast, there is no validated CSF biomarker for PD. We validated our proteomics-discovered multianalyte profile (MAP) in CSF from 95 control subjects, 48 patients with probable AD, and 40 patients with probable PD. An optimal 8-member MAP agreed with expert diagnosis for 90 control subjects (95%), 36 patients with probable AD (75%), and 38 patients with probable PD (95%). This MAP consisted of the following (in decreasing order of contribution): τ, brain-derived neurotrophic factor, interleukin 8, Aβ42, β2-microglobulin, vitamin D binding protein, apolipoprotein (apo) AII, and apoE. This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD.

Original languageEnglish (US)
Pages (from-to)526-529
Number of pages4
JournalAmerican journal of clinical pathology
Issue number4
StatePublished - Apr 2008


  • Alzheimer disease
  • Analyte profile
  • Biomarkers
  • Cerebrospinal fluid
  • Parkinson disease
  • Random forest algorithm

ASJC Scopus subject areas

  • Pathology and Forensic Medicine


Dive into the research topics of 'CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases'. Together they form a unique fingerprint.

Cite this